PMID: 7538695Jan 1, 1995Paper

Hormone refractory disease

Seminars in Surgical Oncology
C Mahler, L Denis

Abstract

Hormone refractory disease is observed in less than 20% of newly diagnosed cases of advanced prostatic cancer. In the majority of cases, hormone refractory disease appears after a median time of 18 months of endocrine manipulation and is attributed to the selection and/or cloning of pre-existing or de novo appearing hormone-independent or resistant cell lines. There are no generally accepted rules for second-line management. The varying sets of criteria used by different study groups make comparisons of widely different regimens very difficult. Actually, it seems reasonable to consider length of survival as the only objective response criterion. This implies, however, that there should be an unanimous definition about the moment of primary treatment failure. Indeed, the detection of hormonal escape is a gradual event and the relative length of survival time depends on the chosen moment of therapy administration. To date, monitoring of prostate specific antigen (PSA) has become the best and primary tool to document progression of disease. Earlier diagnosis based on a rise in PSA levels in patients that are still asymptomatic with a good performance status, might provide the opportunity to treat patients that could profit from th...Continue Reading

References

Sep 1, 1992·The Journal of Steroid Biochemistry and Molecular Biology·R De CosterC Bowden
May 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A SmithM A Friedman
Apr 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A T Van OosteromC Mahler
Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A DupontF Labrie
Jan 1, 1990·Cancer Investigation·R Benson, B Hartley-Asp
Jan 1, 1989·International Urology and Nephrology·I Könyves
Oct 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A V Schally, T W Redding
Jan 1, 1987·The Journal of Urology·A MitreS Arap
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H I Scher, W K Kelly
Dec 15, 1993·Cancer·F C da Silva
Apr 21, 1993·Journal of the National Cancer Institute·M A EisenbergerM J Egorin

❮ Previous
Next ❯

Citations

Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D S ErnstW Parulekar
Mar 23, 2006·Journal of Cellular Biochemistry·Shan-Zhong YangSarki A Abdulkadir
Jan 1, 1997·Urological Research·D W Newling
Jul 9, 2005·Expert Review of Anticancer Therapy·Antonio Jimeno, Michael Carducci
Apr 29, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Giorgia ZadraMassimo Loda
Jun 7, 1997·Lancet·M FrydenbergK W Kaye

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.